Dantari

Dantari is a clinical-stage biotechnology company developing targeted therapies for the treatment of cancer and other diseases. The company is advancing a pipeline of T-HDC (Targeted High Drug-Loaded Conjugates) chemotherapeutics, starting with DAN-222 and next-generation ADC therapy T-HDC technology originating from Caltech. Dantari's HDC and T-HDC platform technologies utilize polymeric conjugates with high drug-to-antibody ratios (DAR), along with precise control and flexibility, to optimize the performance of targeted drug conjugates that can leverage proven targets across a wide range of therapeutic payload options.